Veeva Systems Inc. reports developments in cloud software, data, AI, and consulting for the life sciences industry. Company news commonly covers adoption of the Veeva Vault Platform, including Development Cloud, Quality Cloud, Commercial Cloud, Data Cloud, Vault CRM, and Veeva MedTech applications for clinical, regulatory, quality, commercial, and medical operations.
Updates also include customer standardization projects with pharmaceutical, biotechnology, medical device, and diagnostics companies; product and data offerings such as Link Key People and Veeva AI; fiscal results and subscription revenue trends; and corporate actions such as acquisitions, including the completed purchase of Ostro as a life sciences brand engagement platform.
Veeva Systems (NYSE: VEEV) will host its investor day virtually on November 5, 2026, with presentations broadcast live online. The event begins at 1:30 p.m. PT (4:30 p.m. ET) and concludes at approximately 3:30 p.m. PT. Registration and the live broadcast will be available at ir.veeva.com, with an archived webcast available after the event.
IQVIA (IQV) expanded its partnership with Veeva Systems (VEEV), selecting four Veeva applications as enterprise standards across its clinical development studies. The selected applications are CTMS, eTMF, Study Startup and Site Connect. They will be used across IQVIA studies, extending the companies' previously announced electronic data capture partnership.
All Veeva clinical solutions are also available through IQVIA for sponsors seeking a full Veeva technology stack. IQVIA said the collaboration is intended to give clinical teams a more connected way to work through integration of the companies' technologies. Customers retain flexibility to choose electronic data capture, randomization and trial supply management, and electronic clinical outcome assessment technologies, including IQVIA solutions.
Veeva Systems (NYSE: VEEV) will showcase AI offerings at its R&D and Quality Summit on October 20-21 in Boston. The event will bring together life sciences professionals, including participants from Eli Lilly and Company, Pfizer, Sanofi, UCB, Duke University, and the University of Pennsylvania.
More than 100 sessions will cover AI and automation, connected clinical trials, and quality and manufacturing. Highlights include Veeva Falcon, Vault AI, and new capabilities in Veeva Development Cloud and Veeva Quality Cloud. The summit is open exclusively to life sciences professionals.
Veeva Systems (VEEV) announced that more than 175 emerging biotechs are using Veeva Basics to establish a technology foundation for their operations. The pre-configured and pre-validated applications cover clinical, regulatory, quality, medical, and commercial functions. Biotechs are launching the applications in weeks.
Veeva said the applications can scale as customers move from startup to commercialization. Veeva Submissions Publishing Basics supports submission building and health authority interactions, including bringing regulatory publishing in-house.
Veeva Systems (NYSE: VEEV) announced that its Data Quality System has aggregated and cleaned clinical trial data for more than 1 million subjects. The platform, known as Veeva DQS, has handled data across more than 1,000 studies and generated more than 500,000 automated queries. Veeva said this automation has saved sites and sponsors thousands of hours in data reconciliation.
Upcoming DQS innovations include automated data exchange with Veeva CTMS for risk-based monitoring and AI-assisted classification of study data. The recently announced Veeva Study Builder Agent configures Veeva EDC and DQS directly from a study protocol.
Veeva Systems (VEEV) announced that Servier is standardizing customer reference data across more than 80 countries using Veeva OpenData.
The adoption builds on Servier's existing use of Veeva Link Key People and connects data for its global commercial and medical teams. Servier said centralizing this information will create a unified data foundation to scale artificial intelligence across its affiliates. OpenData is part of Veeva Data Cloud, which also includes Veeva Link and Veeva Compass.
Veeva Systems (VEEV) announced Study Builder Agent on September 24, 2026, to configure clinical-study data systems from study protocols.
The AI agent is designed to set up forms, visits and edit-check rules in Veeva EDC, along with CQL-based listings in Veeva DQS (Data Quality System). It also automates testing, including the generation of test data. The agent uses an organization's existing standards and the CDISC Unified Study Definitions Model to guide the build. Veeva says it can configure studies in as little as one day and produce builds that minimize departures from those standards.
Early adopter availability is planned for December 2026. Study Builder Agent will be part of EDC and will require no additional license.
Veeva Systems (VEEV) announced that another top 20 biopharma has selected its Vault CRM platform, adding to existing commitments from Amgen, Biogen, Eli Lilly and Company, and Regeneron.
Vault CRM now has more than 190 live customers and global commitments from 14 of the top 20 biopharmas/b). The company describes Vault CRM as the next generation of CRM, with new agentic and core capabilities designed to boost field productivity and effectiveness and to support “agentic commercial” engagement with healthcare professionals.Vault CRM is part of the broader Veeva Vault CRM Suite, which connects sales, marketing, and medical teams for customer-centric and compliant multi‑channel engagement across the life sciences industry.
Veeva Systems (VEEV) introduced Veeva Falcon Router, an industry-specific agent designed to identify and route potential safety adverse event reports, product quality complaints, and medical inquiries to appropriate teams. Falcon Router aims to orchestrate triage and routing for biopharma companies of all sizes, reducing the need for manual reconciliation.
The initial focus is on email and web intake channels, including Veeva Ostro, with routed information sent directly to Veeva Safety, Veeva QMS, Veeva MedInquiry, or designated inboxes. Early adopter availability is planned for January 2027. Falcon Router is part of the Falcon Agent Suite, Veeva's suite of agentic labor solutions for life sciences. Veeva reports serving more than 1,500 life sciences customers across large pharmaceutical companies and emerging biotechs.
Veeva Systems (VEEV) announced that Amgen plans to deploy Veeva Vault CRM globally, expanding a collaboration that has lasted more than a decade.
Amgen’s chief information officer said the move to Vault CRM is expected to support faster, more agile delivery of new therapies to patients worldwide. Veeva’s president of commercial strategy described Vault CRM as an agentic commercial foundation to help Amgen reach millions of patients with medicines for difficult diseases.
Vault CRM is part of the Vault CRM Suite, which is described as enabling agentic commercial engagement with healthcare professionals and includes the Agentic Call Report to generate Commercial Evidence and identify hidden treatment barriers.